Clinitech LaboratoryShare price, financial results, shareholding and management
- Market cap
- ₹7 cr
- Stock P/E
- 16.7peers 72.8
- Book value
- ₹40.5
- Price to book
- 0.74
- EV / operating profit
- -
- Market cap to sales
- 0.72
- ROCE · FY26
- 7.2%
- ROE · FY26
- 4.5%
- ROE, 3-year average
- 7.8%
- Operating margin · FY26
- 10.4%peers 16.5%
- Sales growth, 3 years
- 14.3%
- Profit growth, 3 years
- -12.4%
- Debt to equity
- 0.06peers 0.11
- Borrowings
- ₹0.5 cr
- Interest cover
- 9.6×
- Cash from business / op. profit
- -80%
- Debtor days
- 71
- Pledged
- 0.00%
- Promoter holding
- 64.20%
- Change in promoter holding
- +1.78 pts
- Shareholders
- 297
- 52-week high / low
- ₹47 / ₹29
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Clinitech Laboratory share price chart
Close on 30 Oct 2026 · -2.76% on the day · Vol 1,200
Daily prices to 30 Oct 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 30 Oct 2026
- 3 months
- -25.0%
- 6 months
- -25.0%
- 1 year
- -29.4%
- Traded a day, 20 days
- ₹0.01 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +15% | +5% |
| 3 years, a year | +14% | -12% |
| Latest half, H2 FY26 | +6% | -29% |
Clinitech Laboratory revenue and profit growth
Half-yearly results · Profit and lossSales have grown steadily. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.
Clinitech Laboratory half-yearly results
SME companies report every six months · ₹ crore
| H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|
| Sales | 3.06 | 3.34 | 4.08 | 4.16 | 5.08 | 4.39 |
| Expenses | 2.78 | 2.61 | 3.52 | 3.88 | 4.54 | 3.94 |
| Operating profit | 0.28 | 0.73 | 0.56 | 0.28 | 0.54 | 0.46 |
| OPM | 9.2% | 21.9% | 13.6% | 6.7% | 10.6% | 10.4% |
| Interest | 0.04 | 0.06 | 0.04 | 0.02 | 0.05 | 0.02 |
| Depreciation | 0.19 | 0.25 | 0.31 | 0.14 | 0.25 | 0.26 |
| Profit before tax | 0.07 | 0.43 | 0.26 | 0.29 | 0.35 | 0.25 |
| Net profit | 0.07 | 0.30 | 0.22 | 0.17 | 0.30 | 0.12 |
Clinitech Laboratory profit and loss
Full years to March, FY21 to FY26 · ₹ crore, consolidated where reported
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Sales | 4.55 | 6.38 | 6.35 | 6.40 | 8.23 | 9.49 |
| Expenses | 3.72 | 5.31 | 4.99 | 5.41 | 7.40 | 8.50 |
| Operating profit | 0.83 | 1.07 | 1.36 | 0.99 | 0.83 | 0.99 |
| OPM | 18.2% | 16.8% | 21.4% | 15.5% | 10.1% | 10.4% |
| Other income | 0.04 | 0.07 | 0.02 | 0.04 | 0.23 | 0.19 |
| Interest | 0.08 | 0.06 | 0.07 | 0.09 | 0.06 | 0.07 |
| Depreciation | 0.25 | 0.38 | 0.45 | 0.44 | 0.45 | 0.51 |
| Profit before tax | 0.54 | 0.70 | 0.86 | 0.50 | 0.55 | 0.60 |
| Tax rate | 25.9% | 27.1% | 29.1% | 26.0% | 29.1% | 31.7% |
| Net profit | 0.40 | 0.51 | 0.61 | 0.37 | 0.39 | 0.41 |
| EPS ₹ | 6 | 3.40 | 4.07 | 2.20 | 1.71 | 1.84 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Clinitech Laboratory profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a low return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Operating margin | 18.2% | 16.8% | 21.4% | 15.5% | 10.1% | 10.4% |
| Tax rate | 25.9% | 27.1% | 29.1% | 26.0% | 29.1% | 31.7% |
| ROCE | · | 32.5% | 30.2% | 15.1% | 9.2% | 7.2% |
| ROE | · | 31.5% | 28.8% | 12.5% | 6.3% | 4.5% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Clinitech Laboratory debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. It has almost no borrowings. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Clinitech Laboratory balance sheet
At each 31 March · ₹ crore
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Equity capital | 0.67 | 1.50 | 1.50 | 1.68 | 2.28 | 2.28 |
| Reserves | 0.72 | 0.35 | 0.88 | 1.87 | 6.55 | 6.97 |
| Net worth | 1.39 | 1.85 | 2.38 | 3.55 | 8.83 | 9.25 |
| Borrowings | 0.54 | 0.89 | 1.03 | 0.87 | 0 | 0.54 |
| Other liabilities | 0.80 | 0.94 | 2.62 | 1.19 | 2.01 | 1.38 |
| Total liabilities | 2.73 | 3.68 | 6.03 | 5.61 | 10.84 | 11.17 |
| Fixed assets | 0.84 | 1.65 | 1.33 | 1.71 | 2.12 | 2.18 |
| Capital work in progress | 0.08 | 0.41 | 0.56 | 0.94 | 1.01 | 1.25 |
| Investments | 0.09 | 0.14 | 2.02 | 0.07 | 0.07 | 0.07 |
| Other assets | 1.72 | 1.48 | 2.12 | 2.89 | 7.64 | 7.67 |
Clinitech Laboratory cash flow
₹ crore
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Cash from operations | 0.38 | 0.96 | 1.25 | -1.28 | -0.88 | -0.79 |
| Cash from investing | 0.54 | -1.47 | -0.65 | 0.75 | -0.73 | -0.68 |
| Cash from financing | -0.88 | 0.29 | 0.09 | 0.45 | 3.98 | 0.51 |
| Net cash flow | 0.04 | -0.22 | 0.69 | -0.08 | 2.37 | -0.96 |
Working capital
Days
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Debtor days | 45 | 21 | 28 | 34 | 68 | 71 |
| Inventory days | 32 | 40 | 44 | 93 | · | · |
| Days payable | 165 | 131 | 125 | 116 | · | · |
| Cash conversion cycle | -87 | -70 | -53 | 11 | 68 | 71 |
| Working capital days | 43 | -5 | -33 | 22 | 114 | 159 |
Clinitech Laboratory peers and competitors
Listed SME companies in the same industryBy sales, Clinitech Laboratory is number 18 of the 23 listed SME companies in healthcare services.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Maitreya Medicare | 80 | - | 44.9 | -2.5 | -0.7% | 0.80 |
| Invicta Diagnostic | 84 | 17.3 | 32.4 | 4.9 | 30.2% | 0.07 |
| Nidan Laboratories and Healthcare | 19 | 12.4 | 25.5 | 1.5 | 19.0% | 0.16 |
| Aatmaj Healthcare | 50 | 69.7 | 24.3 | 0.7 | 9.7% | 0.41 |
| Aashka Hospitals | 243 | 72.8 | 23 | 3.3 | 22.8% | 0.08 |
| Clinitech Laboratory | 7 | 16.7 | 9.5 | 0.4 | 10.4% | 0.06 |
| KK Shah Hospitals | 31 | - | 9.3 | -0.6 | 8.3% | 0.00 |
| Broach Lifecare Hospital | 8 | 94.4 | 6 | 0.1 | 8.5% | 0.00 |
| Dr Lalchandani Labs | 6 | 104.9 | 4.2 | 0.1 | 16.5% | 0.15 |
| Vanta Bioscience | 15 | 132.0 | 1.8 | 0.1 | 56.0% | 1.80 |
| Global Longlife Hospital and Research | 14 | - | 0 | -1.7 | - | 0.00 |
| Median of the 10 others | 25 | 72.8 | 16.2 | 0.1 | 16.5% | 0.11 |
Clinitech Laboratory shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little more than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Clinitech Laboratory shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 24 | Mar 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|
| Promoters | 61.58% | 61.58% | 62.42% | 64.20% |
| Foreign investors (FIIs) | 0.32% | 0.32% | 0.32% | - |
| Number of shareholders | 346 | 303 | 303 | 297 |
Clinitech Laboratory latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹4.4 cr (+6%), net profit ₹0.1 cr (-29%) on H2 FY25.
- Shareholding, 31 March 2026: promoters 62.42% to 64.20%.
Clinitech Laboratory announcements
4 on record, latest first; each opens the filing on the exchange
- Company UpdateCertificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended September 30, 2026PDF ↗
- Insider Trading / SASTClosure of Trading Window for Insiders the company from Thursday, October 01, 2026 for Unaudited Standalone & Consolidated Financial Results for thr half yera ePDF ↗
- AGM/EGMVoting Results and Scrutinizers Report for voting of AGM held on September 24, 2026 at 11.30 AM through video conferencingPDF ↗
- AGM/EGMProceedings of 16th Annual General Meeting held today i.e September 24, 2026 at 11.30 AM through video conferencingPDF ↗
Clinitech Laboratory annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Clinitech Laboratory share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Clinitech Laboratory's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- iThe shares traded on only 87 days in the past year, so the price, its range and the returns here rest on few trades.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (22,82,400 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY21 to FY26.
- iPrices run to the close on 7 Oct 2026, from the exchange's daily figures.
Questions people ask about Clinitech Laboratory
What does Clinitech Laboratory do?
Clinitech Laboratory is an SME company listed on BSE SME, in healthcare services.
What is the share price of Clinitech Laboratory?
₹30 at the close on 30 Oct 2026, from the exchange's daily figures.
What is the market cap of Clinitech Laboratory?
₹7 cr at the close on 30 Oct 2026, on 22,82,400 shares.
What is the P/E of Clinitech Laboratory?
16.7 times FY26 profit at the close on 30 Oct 2026 (our arithmetic).
What are Clinitech Laboratory's revenue and profit?
Revenue ₹9 cr and profit after tax ₹0 cr in FY26.
Who are the promoters of Clinitech Laboratory?
The promoter group; promoters held 64.20% at 31 March 2026.
What is Clinitech Laboratory's website?
www.ctllab.in
More SME companies like Clinitech Laboratory
Other listed SME companies in healthcare services, the closest in size first, each read from its own documents.
- Broach Lifecare HospitalBROACH · BSE SME · Healthcare ServicesMarket cap ₹8 cr
- Dr Lalchandani LabsDLCL · BSE SME · Healthcare ServicesMarket cap ₹6 cr
- Global Longlife Hospital and ResearchGLHRL · BSE SME · Healthcare ServicesMarket cap ₹15 cr
- Vanta BioscienceVANTABIO · BSE SME · Healthcare ServicesMarket cap ₹16 cr
- Nidan Laboratories and HealthcareNIDAN · NSE Emerge · Healthcare Services · listed 2021Market cap ₹17 cr
- KK Shah HospitalsKKSHL · BSE SME · Healthcare ServicesMarket cap ₹31 cr
Built from 4 exchange announcements, 4 shareholding patterns and 6 years of reported results. Every figure carries its source; where the documents are silent, the page says so.